Jaume Mora

Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes

S. Perez-Jaume, M. Garraus, A. Castañeda, 2023, Cancers.

N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.

W. Gerald, J. Mora, G. Heller, 2001, Medical and pediatric oncology.

Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects

S. Perez-Jaume, A. Castañeda, M. Gorostegui, 2024, Frontiers in oncology.

Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy

C. Lavarino, S. Perez-Jaume, Noelia Salvador, 2024, Cancers.

Treatment of childhood astrocytomas with irinotecan and cisplatin

J. Mora, O. Cruz, S. Perez-Jaume, 2018, Clinical and Translational Oncology.